
Initiatives to Promote the Healthcare Industry in Malaysia

Abd Ghani Abd Aziz Principal Assistant Secretary National Biotechnology Division Ministry of Science, Technology & Innovation



FRAMEWORK FOR THE NATIONAL POLICY ON SCIENCE, TECHNOLOGY AND INNOVATION (NPSTI)





NATIONAL BIOTECHNOLOGY POLICY

The Malaysian Government commits itself to undertake the role of developer and catalyst of the country's biotechnology sector

BRAND STATEMENT

Biotechnology for wealth creation and social well-being

VISION

Position biotechnology as the new economic engine to enhance prosperity and wellness of the nation by 2020 Bioteknologi untuk Kemakmuran Negara dan Kesejahteraan Sosial tri Netegar tri Integer William Article Integer

Bioteknologi untuk Kemakmuran Negara dan Kesejahteraan Sosial

1 Melengkan ke Hadapan



National Biotechnology Policy





3 PHASE STRATEGIE

PHASE I CAPACITY BUILDING 2005 - 2010

mosti

- Provide Biotechnology Development Incentives
- Improve Human Capital & Skills Development
- Improve Job Creation
- Intensify R&D

- Accelerate Development In Agricultural, Healthcare & Industrial Biotechnologies
- Strengthen Legal & IP Framework
- Develop Bioinformatics
- Develop Bionexus Companies

PHASE II SCIENCE TO BUSINESS 2011 - 2015


- Intensify RDI Participation
- Expand Pool of Knowledge Workers
- Develop Expertise In Drug Discovery & Development On Biodiversity & Natural Resources
- Improve New Products Development
- Intensify Technology Acquisition
- Develop Capability In Technology Licensing
- Create Global Brands

PHASE III GLOBAL BUSINESS 2016 - 2020

- Consolidate Strengths & Capabilities In Biotechnology Development
- Intensify Expertise & Strength In Drug Discovery & Development
- Create Leadership In Innovation & Technology Licensing
- Create Greater Value Through Global Malaysian Companies
- Strengthen Branding Of Malaysia As A Global Biotech Hub

BIOTECH CLUSTER CORE BUSINESS

most



industry

Pelaksanaan Dasar Bioteknologi Negara

2005



- ✓ Genom Computing Centre (GCC)
- ✓ biotech@community

2009 ✓ Bio-IAP →



✓ Pelancaran Program BTP

✓ Penubuhan Majlis Bioetika Negara

Fasa II (2011-2015) R&D ke pasaran

✓ BioBorneo
 ✓ National
 Biotechnology
 Seminar

2014

✓ Pengkorporatan
 NIBM

✓ Bio- Accelarat

✓ BioShoppe



2020

Rice

Fasa III (2016-2020) Perniagaan Global


2020

CONK B

- Syarikat bioteknologi bertaraf global
- ✓ BioMalaysia sebagai Hab Global




SCOPE & FLEXIBILITY



3.1 PENYELIDIKAN & PEMBANGUNAN BIOTEKNOLOGI Pembiayaan Dana R&D Bioteknologi (2011–

2015)



Jumlah Keseluruhan RM100 juta

R&D HEALTHCARE BIOTECHNOLOGY



MARDI

Product : Dermaco Tm M7

A novel value added virgin coconut oil based product with broad spectrum of antimicrobial activity against selected pathogenic microorganism

(1 Patent filed)



MOST

EntoGeneX Industries Sdn. Bhd.


Product : Biolarvicide Mostique

The production of Trypsin Modulating Oostatic Factor (TMOF), a small mosquito-derived peptide expressed within the *Pichia Pastoris* yeast cells to stops the digestive protein synthesis in larval and adult mosquitoes



BIOTECHNOLOGY COMMERCIAL READY PROTOTYPES/ PRODUCTS

SEMI-BEFINER CABBAGEENAN



(TF1107B040)

(OMNI-GEL SDN BHD) gankiantee@gmail.com

DESCRIPTION

Upgraded facilities for production of Food Grade Carrageenan from Non-Grade food carrageenan in compliance with GMP requirement and HACCP quality control to produce functional products such as drug delivery capsules and new hydrocolloids.

NOVELTY OF THE PRODUCT

Wide range of usage for production of food additives, binders and emulsifier and functional products



CULTIVATED KACIP FATIMAH PLANTS



(TF0707B004)

PHARMANIAGA BERHAD

DESCRIPTION


Pharmaniaga Berhad has accomplished the research on propagation and cultivation of Kacip Fatimah (Labisla Pumila var alata) plants according to Good Agriculture Practice (GAP), Skim Akreditasi Malaysia (SALM) in a old oil palm plantation.

Cultivated Kacip Fatimah will give advantages to ensure sustainable Kacip Fatimah source to meet market demand, preserve wild forest and also to served as corporate social responsibility to small contract farmers.




BIOTECHNOLOGY COMMERCIAL READY PROTOTYPES/ PRODUCTS

STEM CELL REGENERATIVE THERAPHY DESCRIPTION



NOVELTY OF THE PRODUCT

The regeneration of hyaline cartilage with the novel therapy method that comprises of arthroscopic subchondral drilling, postoperative intra-articulsar injections of autologous pheripheral blood stem cells in combination with hyaluronic acid



28th Marsh Perior.

ICBS II


(TF0409B104) TECHNOFUND

DATUK DR. AHMED TASIR LOPE (Inno Bio Ventures Sdn Bhd) www.innobioventures.com



BIOTECHNOLOGY COMMERCIAN READY PROTOTYPES/ PRODUCTS

TONGKAT ALI HAIBY BOOT



(TF0508B064)

Dr. Nor Hasnida Hassan (FRIM) hasnida@from.gov.my

DESCRIPTION

The Tongkat Ali hairy root culture considered as the best alternative and promising sources for the production of Tongkat Ali biologically active compounds for both commercial and scientific applications as well as to ensure adequate supply for both herbal industries and conservation purposes.

NOVELTY OF THE PRODUCT

Faster production of Tongkat Ali hairy root through bioreactor technology in approximately 3 months as compared to conventional method (5 years).

Patent: P2010003919 (Pending)

TECHNOFUND









Contracts secured with Indian and Korean companies

Award at 2nd BioSpectrum Asia Pacific Awards







Successful humanisation of antibody

"Emerging Company of the Year 2010"

Using the technology licensed from Centre of Molecular Immunology (CIM), IBL has successfully humanised 2 anti cancer antibodies targeted for colorectal cancer.
IBL is currently conducting the animal study in mouse.



Strategic partnerships with global companies


- Established partnership with Boehringer Ingelheim, GE Healthcare, Centre of Molecular Immunology (CIM), Cuba and CEVEC GmbH.
- Member of MIT Centre for Biomedical Biomanufacturing Alliance.



Establishment of the FIRST cGMP biomanufacturing facility in Malaysia

- •Biologics manufacturing using recombinant DNA in mammalian cell
- -large-scale production of therapeutic proteins to treat a variety of diseases.

Inno Biologics FIRST cGMP biomanufacturing facility in Malaysia²²





Malaysian Institute of Pharmaceuticals & Nutraceuticals

A centre of excellence for commercializationdriven R&D in healthcare biotechnology

THRUST 2 HEALTHCARE BIOTECHNOLOGY DEVELOPMENT



Research Focus:

Discovery of functional food and drug from natural tropical resources for healthcare biotechnology development

<u>Platform</u>: Bioactive Compunds, Bioprocessing & Advanced Drug Delivery System





Mission

MOSTI

To implement R&D, develop human capital & practice, s trengthen strategic collaboration in global healthcare biotechnology leading to commercialization



Development of Natural Products Library from Malaysian biodiversity for systematic discovery of potential active therapeutic agents for Obesity




504 Plant Species



552 crude extracts Methanol and Water extract









1000 Partitions




Isolated Compounds



Search keyword			anim 👻 💧 Change Theme 🛩
MAIN	Home / Dashboard		
🕈 Home			
O About Us	III Dataset	🔳 Databa	se Stat
Q Search	Info Researcher Grant Plant Extraction Partition Fractions Compound	↑ 50	0 Plant Information
🔲 Dataset	Microbial	t 2	3 Researcher Information
EDITOR		÷ 55	2 Extraction Information
Add Plant List	IPharm Natural Product Bank	† 58	8 Partition Information
Add Researcher		† 19	0 Fractions Information
Add Grant List	Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm)	t	0 Grant Information
New Extraction		↑ 3 Information	2 Chemical Compound
New Partition			0
New Fractions		1	0 Microbial Information
III New Compound			





MyNature 50000 comprises a chemical library; extracts, fractions and compounds of local Malaysian plants for research purposes. This library is developed by Natural Product Drug Discovery (NPDC) team under Malaysian Institutes of Pharmaceuticals and Nutraceuticals (IPharm).

Our goal is to create a global resource for natural product. To achieve this purpose, we collaborate in construction of chemical library, validation of biological activities, and determination of target molecules.



A RAPID COST EFFECTIVE APPROACH

CHEAP, EASY, FAST AND REPRODUCIBLE

EASY ACCESS TO A PARTICULAR PLANT CHEMICAL PROFILE AND ACTIVITY

CONVENIENT AND EASY ACCESS TO MALAYSIAN NATURAL PRODUCT

WE PROVIDE SOLUTIONS FOR:

PLANT EXTRACTS PLANT PARTITIONS PLANT FRACTIONS PURE COMPOUNDS

READY FOR SALES

DIVERSITY SET

It is our most popular competitively priced collection of 500 plant species

Dried plant species also available in stock

Upon customer request the sample stock also available in DMSO solvent


Price depends on the type, number of extract or compounds selected and a sample size.

1mg samples size in dry form varies from RM35-60

my

BioMedical within the Bio-Based Industry

MOSTI




The application of **bio-based technologies is the GAME CHANGER** that transform conventional processes and industries in the bioeconomy into major contributors to the national economy

Bioeconomy Transformation Programme

most

(BTP)

A platform for the private sector to channel and maximise commercial opportunities from bio-based technologies






Benefits of BTP National Visibility and Government Support



BTP Trigger Projects are expected to generate impacts on GNI, job creation and investment





THANK YOU

